Abstract
We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m2 PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ahlgren JD (1996) Chemotherapy for pancreatic cancer. Cancer 78, (Suppl 3):654–663
Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S and Giaccone G (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11: 697–700
Beppu T, Ohara C, Yamaguchi Y, Ichihara T, Yamanaka S, Katafuchi S, Ikei S, Mori K, Fukushima S and Nakano M (1991) A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 68: 2555–2560
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
Falkson G, Moertel CG, Lavin P, Pretorius FJ and Carbone PP (1978) Chemotherapy studies in primary liver cancer. A prospective randomized clinical trial. Cancer 42: 2149–2156
Falkson G, MacIntyre J, Shutt AJ, Coetzer B, Johnson LA, Simson IW and Douglass HO Jr (1984) Neocarzinostatin versus mAMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 2: 581–584
Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Okui K and Morimoto Y (1985) Biodegradable Mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. Cancer 56: 2404–2410
Gabizon A, Meshorer A and Barenholz Y (1986) Comparative long term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77: 459–466
Gabizon A and Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 54, (Suppl 4):15–21
Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R and Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093–3100
Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mossner J and Berr F (2000) A phase II study of pegylated liposomal doxorubicin for the treatment of advanced hepatocellular carcinoma. Ann Oncol 11: 113–114
Hoffman K and Glimelius B (1998) Evaluation of benefit of chemotherapy in patients with upper gastrointestinal cancer. Acta Oncol 37: 651–659
Hong RL, Tseng YJ and Chang FH (2000) Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. Ann Oncol 11: 349–353
Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J and Nielsen S (2001) Randomised phase II trial of pegylated liposomal doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma group. Eur J Cancer 37: 870–877
Konno T, Maeda H, Iwai K, Tashiro S, Maki K, Morinaga T, Mochinaga M, Hiraoka T and Yokoyama I (1983) Effect of arterial administration of high-molecular-anticancer agents SMANC with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19: 1053–1065
Lai C-L, Wu P-C, Chan GC-B, Lok AS and Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62: 479–483
Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P and Poynard T (1998) Review article: Overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis?. Aliment Pharmacol Ther 12,
Muggia FM, Hainsworth JD and Jeffers S (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987–993
Onohara S, Kobayashi H, Itoh Y and Shinohara S (1988) Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin-II induced hypertension for treatment of hepatocellular carcinoma. Acta Radiologica 29: 197–202
Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D and Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 3185–3191
Sasaki Y, Imacka S and Kasugai H (1997) A new approach to chemoembolisation therapy for hepatoma using ethiodized oil, cisplatin, gelatin sponge. Cancer 60: 1194–1203
Scheithauer W, Kornek GV, Raderer M, Hejna M, Valencak J, Miholic J, Kovats E, Lang F, Funovics J, Bareck E and Depisch D (1999) Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 80: 1797–1802
Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P and Gangl A (2001) Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 48: 103–109
Simonetti RG, Liberati A, Angiolini C and Pagliaro L (1997) Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 8: 117–136
Toma S, Tucci A, Villani G, Carteni G, Spadini N and Palumbo R (2000) Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 20: 485–491
Zou Y, Horikoshi Y, Kasagi T, Gu X and Perez-Soler R (1993) Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery. Cancer Chemother Pharmacol 31: 313–318
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Schmidinger, M., Wenzel, C., Locker, G. et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85, 1850–1852 (2001). https://doi.org/10.1054/bjoc.2001.2149
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2149
Keywords
This article is cited by
-
Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check
Frontiers of Medicine (2020)
-
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
British Journal of Cancer (2005)
-
Recent advances with liposomes as pharmaceutical carriers
Nature Reviews Drug Discovery (2005)